Clinical and functional effectiveness of anti-TNF therapy in patients with rheumatoid arthritis
Journal of Translational Medicine volume 9, Article number: P46 (2011)
To evaluate the clinical and functional activity of patients with rheumatoid arthritis at one and two years after starting anti-TNF therapy.
Patients and methods
This is a retrospective study of 50 RA patients, who started ANTI-TNF theraphy between June 2006 and july 2009. The main variables in the study were: DAS28, HAQ and pain VAS. We analyzed evolution after 1 year and 2 years from the beginning of the treatment. The comparison with the basal state was made with Student’s t test. The statistical study was analyzed by the SPSS 18,0.
The study includes 50 patients, 66% female, with RF in 76% and erosions in 64%, treated with etanercept (28), adalimumab (13) and infliximab (9). Most of them (70%) had recieved at least 2 FAMES before biological. In the below table we compare changes in clinical parameters for different biologics after one and two years.
All anti-TNF significantly improve disease activity, functional status and pain VAS after the first year. This improvement continues but not significantly increases the second year.
Etanercept is the only drug with a significant reduction for HAQ, DAS28 and pain VAS.
About this article
Cite this article
Martínez-Pérez, R., Uceda, J., León, M. et al. Clinical and functional effectiveness of anti-TNF therapy in patients with rheumatoid arthritis. J Transl Med 9 (Suppl 2), P46 (2011). https://doi.org/10.1186/1479-5876-9-S2-P46